![]() ![]() After PSM (1:1 ratio), 458 patients remained. Results: There were 733 eligible ESCC patients. #Linkdoc data scientist plusPatients diagnosed with stage II-III ESCC treated with adjuvant chemotherapy (cisplatin plus docetaxel or LBP plus docetaxel) between January 2013 and December 2016 were selected from 6 centres in China. Methods: A multicentre retrospective study was performed using propensity score matching (PSM) with the Medicine-LinkDoc database. We compared LBP plus docetaxel with cisplatin plus docetaxel as adjuvant chemotherapy in ESCC patients to determine the effects on overall survival (OS) and toxicity. ![]() Objectives: Lobaplatin (LBP), a third-generation cisplatin derivative has shown promising activity and few side effects in oesophageal squamous cell carcinoma (ESCC) in previous reports.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |